U.S. Meibomian Gland Dysfunction Market Size, Landscape, Industry Analysis, Business Outlook, Current and Future Growth
Dry eye
syndrome (DES), also known as keratitis sicca and keratoconjunctivitis sicca,
is caused by meibomian gland dysfunction. Patients with DES experience ocular
surface damage, tear film instability, and visual disturbance. Tear film covers
the ocular surface and is composed of three intertwined layers: a superficial
lipid layer produced by meibomian glands that aids in reducing tear evaporation
and uniform tear spreading, a middle thick aqueous layer produced by lacrimal
glands, and an innermost hydrophilic mucin layer produced by conjunctival
goblet cells and ocular surface epithelium.
The investigation reveals the total
assessment and veritable components of the Meibomian Gland Dysfunction Market
in the United States. The research analysts provide a detailed description of
the value chain as well as an analysis of its distributors. This Market study
contains extensive data that improves the understanding, scope, and application
of this report. The report also includes the market's trends and expected prospects,
providing an intellectual understanding
of the U.S. Meibomian
Gland Dysfunction Market.
People
who frequently use computers or video screens are at a higher risk of
developing meibomian gland dysfunction, as prolonged use of screens can result
in decreased blinking and tear production. Due to extensive use for social and
professional purposes, digital device usage has increased significantly in
recent years among all age groups. Blue light emitted by digital screens can
cause dry eyes and meibomian gland dysfunction. Blue light (400–500 nm)
exposure can be harmful to the retina. Longer-term and lower-intensity light
exposure can also cause photochemical damage in the eyes.
The increasing demand for faster and
non-invasive treatment approaches that provide long-term relief from dry eye
symptoms is expected to drive the growth of the dry eye treatment device
market. For example, an intense pulsed light (IPL) session lasts about 15-20
minutes, and 4-5 sessions are recommended to provide long-term relief from dry
eye symptoms. As a result, it is gaining popularity among patients who are
dissatisfied with the frequent application of eye drops to alleviate dry eye
symptoms. Globally, the increasing prevalence of dry eye syndrome and U.S. meibomian gland dysfunction
market growth.
Pfizer, Inc., AbbVie Inc., Johnson and Johnson
Vision Care Inc., Bausch Health Companies Inc., Novartis AG, Santen
Pharmaceutical Co., Ltd., I-MED Pharma Inc., OASIS Medical, Sentiss Pharma Pvt.
Ltd., RegeneRx, and Akorn, Inc. are the primary market participants.
Comments
Post a Comment